Core Viewpoint - Xianjian Technology (01302) saw a significant increase in stock price, rising by 4.07% to HKD 1.79, with a trading volume of HKD 37.76 million following the approval of its innovative medical device by the National Medical Products Administration [1] Group 1: Product Approval - The Concave Supra integrated three-branch reconstruction system, co-developed by Professor Shu Chang from the National Center for Cardiovascular Diseases and Xianjian Technology, has been approved for entry into the special review process for innovative medical devices, known as the "green channel" for national innovation [1] - This marks the 17th product from Xianjian Technology to be approved for the national innovation "green channel," highlighting the company's commitment to research and development in the medical device sector [1] Group 2: Product Features - The CS stent system is designed for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, representing a global first in providing a solution for integrated three-branch reconstruction without brain ischemia [1] - The product will complement Xianjian's existing innovative product matrix for aortic arch branch reconstruction, including chimney technology and in-situ fenestration techniques, thereby offering a comprehensive solution for endovascular treatment of aortic arch lesions [1]